Synapse - Works

Results (5712)

Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; An open-label, multicenter, phase 1b study

Meeting Abstract

Roboz, G. J.; Pabst, T.; Aribi, A.; Brandwein, J. M.; Döhner, H.; Fiedler, W.; Gandini, D.; Geddes, M.; Hou, J. Z.; Howes, A. J.; more...
Blood (2021)

Fulltext@MSK | Save

The incidence and impact of clostridioides difficile infection (CDI) on outcomes after allogeneic hematopoietic cell transplant (alloHCT) - a CIBMTR study

Meeting Abstract

Ramanathan, M.; Savani, B. B.; He, N. Y.; Kim, S.; Chen, M.; Chemaly, R.; Dandoy, C. E.; Perales, M. A.; Riches, M. L.; Ustun, C.
Blood (2021)

Fulltext@MSK | Save

Overall survival by best overall response with tabelecleucel in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following solid organ or allogeneic hematopoietic cell transplant

Meeting Abstract

Prockop, S.; Gamelin, L.; Dinavahi, R.; Sun, Y.; Zhao, W. Z.; Galderisi, F.; Mehta, A.
Blood (2021)

Fulltext@MSK | Save

Multicenter, open-label, phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)

Meeting Abstract

Prockop, S.; Mahadeo, K. M.; Beitinjaneh, A.; Choquet, S.; Stiff, P.; Reshef, R.; Satyanarayana, G.; Dahiya, S.; Parmar, H.; Ye, W.; more...
Blood (2021)

Fulltext@MSK | Save

Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis

Meeting Abstract

Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

Metformin for treatment of cytopenias in children and young adults with Fanconi anemia

Meeting Abstract

Pollard, J. A.; Furutani, E. M.; Liu, S. S.; Esrick, E. B.; Cohen, L.; Bledsoe, J.; Lu, K.; Ramirez, M. J.; Surralles, J.; Malsch, M.; more...
Blood (2021)

Fulltext@MSK | Save

Quality of life in patients <=70 years of age with chronic lymphocytic leukemia treated frontline with ibrutinibrituximab versus fludarabine cyclophosphamide rituximab: Analysis from ECOG-ACRIN E1912

Meeting Abstract

Pophali, P. A.; Wang, X. V.; Zhao, F.; Kay, N. E.; Hanson, C. A.; Thomas, M. L.; O'Brien, S. M.; Barrientos, J.; Paietta, E. M.; Leis, J. F.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies

Meeting Abstract

Patel, M. R.; Monga, V.; Jauhari, S.; Stevens, D.; Masarova, L.; McKean, M.; Mauro, D.; Viscusi, J.; Scherle, P.; Bhagwat, N.; more...
Blood (2021)

Fulltext@MSK | Save

Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial

Meeting Abstract

Patel, P.; Ruppert, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
Blood (2021)

Fulltext@MSK | Save